Does the media refer more to PBYI or ADMA?

In the previous week, ADMA Biologics had 12 more articles in the media than Puma Biotechnology. MarketBeat recorded 15 mentions for ADMA Biologics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat ADMA Biologics' score of 0.23 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PBYI or CTMX?

In the previous week, CytomX Therapeutics had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 9 mentions for CytomX Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat CytomX Therapeutics' score of 0.61 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer TRDA or PBYI?

In the previous week, Entrada Therapeutics had 18 more articles in the media than Puma Biotechnology. MarketBeat recorded 21 mentions for Entrada Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat Entrada Therapeutics' score of 0.21 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDX or PBYI?

In the previous week, Syndax Pharmaceuticals had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat Syndax Pharmaceuticals' score of -0.22 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RXRX or PBYI?

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Puma Biotechnology. MarketBeat recorded 11 mentions for Recursion Pharmaceuticals and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat Recursion Pharmaceuticals' score of 0.62 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Puma Biotechnology (PBYI) Competitors

$8.83 +0.12 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$8.83 0.00 (0.00%)

As of 04:34 PM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, SNDX, and RXRX

Should you buy Puma Biotechnology stock or one of its competitors? Puma Biotechnology's main competitors and comparable companies include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Syndax Pharmaceuticals (SNDX), and Recursion Pharmaceuticals (RXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Puma Biotechnology compare to ADMA Biologics?

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Puma Biotechnology has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Puma Biotechnology currently has a consensus price target of $6.00, suggesting a potential downside of 32.05%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 97.11%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$231.24M	1.97	$31.11M	$0.52	16.98
ADMA Biologics	$512.28M	4.28	$146.93M	$0.70	13.53

ADMA Biologics has a net margin of 32.98% compared to Puma Biotechnology's net margin of 11.50%. ADMA Biologics' return on equity of 40.17% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	21.34%	13.04%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, ADMA Biologics had 12 more articles in the media than Puma Biotechnology. MarketBeat recorded 15 mentions for ADMA Biologics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat ADMA Biologics' score of 0.23 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Puma Biotechnology has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$231.24M	1.97	$31.11M	$0.52	16.98
CytomX Therapeutics	$76.20M	9.61	-$17.37M	-$0.50	N/A

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 32.05%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 254.17%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Puma Biotechnology has a net margin of 11.50% compared to CytomX Therapeutics' net margin of -435.21%. Puma Biotechnology's return on equity of 21.34% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	21.34%	13.04%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

In the previous week, CytomX Therapeutics had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 9 mentions for CytomX Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat CytomX Therapeutics' score of 0.61 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Puma Biotechnology beats CytomX Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Entrada Therapeutics had 18 more articles in the media than Puma Biotechnology. MarketBeat recorded 21 mentions for Entrada Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat Entrada Therapeutics' score of 0.21 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a net margin of 11.50% compared to Entrada Therapeutics' net margin of -3,537.73%. Puma Biotechnology's return on equity of 21.34% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Puma Biotechnology	11.50%	21.34%	13.04%

Entrada Therapeutics presently has a consensus target price of $17.75, indicating a potential upside of 137.94%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 32.05%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.43	-$143.75M	-$3.96	N/A
Puma Biotechnology	$231.24M	1.97	$31.11M	$0.52	16.98

Summary

Puma Biotechnology beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Puma Biotechnology has a net margin of 11.50% compared to Syndax Pharmaceuticals' net margin of -87.52%. Puma Biotechnology's return on equity of 21.34% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Puma Biotechnology	11.50%	21.34%	13.04%

61.3% of Puma Biotechnology shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Puma Biotechnology has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$252.25M	6.97	-$285.42M	-$2.51	N/A
Puma Biotechnology	$231.24M	1.97	$31.11M	$0.52	16.98

Syndax Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Syndax Pharmaceuticals currently has a consensus price target of $41.91, indicating a potential upside of 111.24%. Puma Biotechnology has a consensus price target of $6.00, indicating a potential downside of 32.05%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Syndax Pharmaceuticals had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat Syndax Pharmaceuticals' score of -0.22 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Puma Biotechnology beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Puma Biotechnology. MarketBeat recorded 11 mentions for Recursion Pharmaceuticals and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.81 beat Recursion Pharmaceuticals' score of 0.62 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a net margin of 11.50% compared to Recursion Pharmaceuticals' net margin of -945.94%. Puma Biotechnology's return on equity of 21.34% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Puma Biotechnology	11.50%	21.34%	13.04%

Recursion Pharmaceuticals presently has a consensus target price of $8.10, indicating a potential upside of 156.33%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 32.05%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	22.42	-$644.76M	-$1.04	N/A
Puma Biotechnology	$231.24M	1.97	$31.11M	$0.52	16.98

Summary

Puma Biotechnology beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$455.81M	$3.71B	$6.97B	$13.05B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	16.98	10.68	269.86	25.30
Price / Sales	1.97	1,293.47	598.68	101.54
Price / Cash	10.67	103.01	70.53	50.75
Price / Book	3.41	17.49	13.08	6.33
Net Income	$31.11M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-0.90%	1.77%	1.14%	1.08%
1 Month Performance	6.64%	1.63%	1.81%	1.04%
1 Year Performance	65.98%	56.45%	67.69%	20.77%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	1.2508 of 5 stars	$8.83 +1.4%	$6.00 -32.0%	+64.3%	$455.81M	$231.24M	16.98	200
ADMA ADMA Biologics	3.9646 of 5 stars	$9.97 +2.2%	$18.67 +87.3%	-45.3%	$2.31B	$512.28M	14.24	530
CTMX CytomX Therapeutics	3.1767 of 5 stars	$3.45 +0.1%	$12.00 +248.3%	+89.3%	$584.60M	$76.20M	N/A	170	Analyst Forecast
TRDA Entrada Therapeutics	3.1733 of 5 stars	$7.20 +3.6%	$17.50 +143.1%	+40.0%	$279.59M	$25.42M	N/A	110	Analyst Forecast Analyst Revision
SNDX Syndax Pharmaceuticals	2.122 of 5 stars	$20.24 -0.6%	$41.91 +107.1%	+41.9%	$1.79B	$252.25M	N/A	110	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, SNDX, and RXRX

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Syndax Pharmaceuticals?

Summary

How does Puma Biotechnology compare to Recursion Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, SNDX, and RXRX

How does Puma Biotechnology compare to ADMA Biologics?

Which has more volatility and risk, PBYI or ADMA?

Do analysts prefer PBYI or ADMA?

Which has preferable valuation and earnings, PBYI or ADMA?

Is PBYI or ADMA more profitable?

Does the media refer more to PBYI or ADMA?

Do insiders and institutionals hold more shares of PBYI or ADMA?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Which has more volatility and risk, PBYI or CTMX?

Do institutionals & insiders have more ownership in PBYI or CTMX?

Which has better earnings and valuation, PBYI or CTMX?

Do analysts recommend PBYI or CTMX?

Is PBYI or CTMX more profitable?

Does the media favor PBYI or CTMX?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Do insiders and institutionals believe in TRDA or PBYI?

Does the media prefer TRDA or PBYI?

Is TRDA or PBYI more profitable?

Do analysts recommend TRDA or PBYI?

Which has more risk and volatility, TRDA or PBYI?

Which has better earnings & valuation, TRDA or PBYI?

Summary

How does Puma Biotechnology compare to Syndax Pharmaceuticals?

Is SNDX or PBYI more profitable?

Do insiders & institutionals believe in SNDX or PBYI?

Which has higher valuation & earnings, SNDX or PBYI?

Which has more risk & volatility, SNDX or PBYI?

Do analysts recommend SNDX or PBYI?

Does the media favor SNDX or PBYI?

Summary

How does Puma Biotechnology compare to Recursion Pharmaceuticals?

Do institutionals & insiders believe in RXRX or PBYI?

Which has more volatility and risk, RXRX or PBYI?

Does the media prefer RXRX or PBYI?

Is RXRX or PBYI more profitable?

Do analysts prefer RXRX or PBYI?

Which has preferable valuation and earnings, RXRX or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools